Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

RECOMMENDED

Pulmonary Fibrosis

Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry

★ 1 Recommended by Dr Martin Frey, Faculty Member

Chest.

Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.

doi: 10.1016/j.chest.2019.12.041.

RECOMMENDED

Pulmonary Fibrosis

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Respir Res.

Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS

doi: 10.1186/s12931-020-01458-1.

RECOMMENDED

Pulmonary Fibrosis

Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Ann Am Thorac Soc

Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH

doi: 10.1513/AnnalsATS.202007-901OC

RECOMMENDED

Pulmonary Fibrosis

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

N Engl J Med.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators

doi: 10.1056/NEJMoa1811737.

COMMENTED

Pulmonary Fibrosis

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials

Lancet Respir Med.

Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR

doi: 10.1016/

Pulmonary Fibrosis

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study

Lancet Respir Med.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL

doi: 10.1016/S2213-

RECOMMENDED

Pulmonary Fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Belhassen M, Dalon F, Nolin M, Van Ganse E

doi: 10.1186/s12931-021-01714-y

RECOMMENDED

Further Publications

United States Pulmonary Hypertension Scientific Registry (USPHSR): Baseline Characteristics

★ 2 Recommended by Dr Martin Frey, Faculty Member

Chest.

Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG, Simms R, Fortin T, Safdar Z, Burger CD, Frantz RP, Hill NS, Airhart S, Elwing J, Marc SR, White J, Robbins IM, Chakinala MM

doi: 10.1016/j.chest.2020.07.088.

RECOMMENDED

Pulmonary Fibrosis

Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis-A Six-Month Follow-Up Study in Patients Treated with Pirfenidone

★ 1 Recommended by Dr Martin Frey, Faculty Member

J Clin Med.

Jaskiewicz K, Mycroft K, Maskey-Warzechowska M, Paralusz K, Siemiez N, Nejman-Gryz P, Barnas M, Krenke R, Gorska K

doi: 10.3390/jcm9082523.

Related content

Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

United States Pulmonary Hypertension Scientific Registry (USPHSR): Baseline Characteristics

Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis-A Six-Month Follow-Up Study in Patients Treated with Pirfenidone